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Bauhinia bauhinioides Cruzipain Inhibitor (BbCI) is a cysteine protease inhibitor highly homologous to plant Kunitz-type inhibitors.
However, in contrast to classical Kunitz family inhibitors it lacks cysteine residues and therefore disulfide bridges. BbCI is also distinct in
the ability to inactivate enzymes belonging to two different classes, cysteine and serine proteases. Besides inhibiting the cysteine protease
cruzipain, BbCI also inhibits cathepsin L and the serine proteases HNE (human neutrophil elastase) and PPE (porcine pancreatic elas-
tase). Monoclinic crystals of the recombinant inhibitor that diffract to 1.7 A˚ resolution were obtained using hanging drop method by
vapor diffusion at 18 C. The refined structure shows the conservative b-trefoil fold features of the Kunitz inhibitors. In BbCI, one of
the two characteristic S–S bonds is replaced by the water-mediated interaction between Tyr125 and Gly132. In this work we explore
the structural differences between Kunitz-type inhibitors and analyze the essential interactions that maintain the protein structural sta-
bility preserving its biological function.
 2007 Elsevier Inc. All rights reserved.
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sources and they have been associated with diverse
events as plant evolution [1,2] and protection against
microorganism invasion and insect attack [3,4]. Among
the many classes of plant inhibitors, the Kunitz family
is the best characterized probably due their abundance
in seeds [1,2].
Extracts from some Bauhinia species are used in tradi-
tional medicine for the diabetes treatment [5,6]. We previ-
ously isolated an inhibitor from seeds of Bauhinia
bauhinioides, Cesalpinoideae, a plant known in Brazil by
the trivial name of ‘‘cow paw’’ due the shape of its leaves
[7]. This inhibitor was named BbCI, Bauhinia bauhinioides
Cruzipain Inhibitor [8], since it inhibits cruzipain, the
major cysteine protease isolated of Trypanosoma cruzi0006-291X/$ - see front matter  2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.bbrc.2007.06.144
* Corresponding author. Fax: +55 11 5572 3006.
E-mail address: olivaml.bioq@epm.br (M.L.V Oliva).and cruzain (Kiapp 0.3 nM), its recombinant form [9]. Try-
panosoma cruzi is the causative agent of Chagas’ disease,
the parasitic infection that remains as one of the leading
causes of heart disease in Latin America [10].
Most curiously, this BbCI shows inhibitory properties
against enzymes of two different classes, cysteine and ser-
ine proteases. We have verified that BbCI inhibits por-
cine pancreatic elastase (Kiapp 40 nM), and human
neutrophil elastase (Kiapp 5.3 nM), a key enzyme
involved in inflammatory processes [8,11]. In vitro, BbCI
also inhibits cathepsin L (Kiapp 2.2 nM) [8], and in con-
trast, it does not affect the activity of cathepsin B,
cathepsin V and cathepsin X, very similar papain-like
proteases [8].
We previously reported a Bauhinia bauhinioides Kalli-
krein Inhibitor, BbKI, an 18 kDa protein isolated from
the same plant seeds, that although displaying a high
(84%) primary structure identity, differs from BbCI by
inhibiting plasma kallikrein (Kiapp 2.4 nM) and plasmin
Fig. 1. The overall structure of rBbCI. rBbCI has a b-trefoil fold, formed
by six two-stranded hairpins. Three of these form a barrel structure (in
green) and the other three are in a triangular array that caps the barrel (in
red). (For interpretation of the references in color in this figure legend, the
reader is referred to the web version of this article.)
Table 1
Data collection and refinement statistics
Data collection Monoclinic
Group space P21
Resolution (A˚) 26.82–1.7 (2.06  1.7)a
Unit-cell parameters (A˚, o) a = 61.96, b = 41.32,
c = 63.53, b = 98.46
Rsym
b (%) 8.2 (43.4)a
Number of observations 505658
Unique reflections 37751
Completeness (%) 95.2 (91.9)a
Rmerge (%) 8.2 (43.4)
I/r (I) 7.0 (1.7)
Refinement
Final Rc, Rfree (F > 0) 0.207, 0.256
Number of of residues per monomer 163
Number of solvent molecules 239
Average B values (A˚2): Protein 19.11
Average B values (A˚2): Water 29.56
R.m.s.d. bonds (A˚) 0.022
R.m.s.d. angles (o) 1.98
Ramachandran plot (%)
Residues in most favorable regions 92.2
Residues in additional allowed regions 7.4
Residues in generously allowed regions 0.4
Residues in disallowed regions 0
a Numbers in parentheses refer to the highest resolution shell.
b Rsym =
P
|I – (I)|/
P
|. (I) is the average intensity of symmetry-related
observations of a unique reflection.
c R =
P
|Fo – Fc|/
P
Fo. Rfree is calculated as R but for 10% of the
reflections excluded from all refinement.
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strated by these atypical Kunitz inhibitors were confirmed
by the recombinant proteins [14].
One of the distinct features of the plant Kunitz (STI)
family is the presence of two highly conserved disulfide
bridges. We have characterized a new subclass of Kunitz
inhibitor with only one disulfide bridge [15,16] or no disul-
fide bridges [17]. The BbCI primary structure presents no
cysteine residues, and BbKI bears only one cysteine residue
in the C-terminal region. The absence of cysteine residues
distinguishes BbCI from classical Kunitz inhibitors where
the disulfide bridges contribute to their stability and bio-
logical activity.
Here, we report the three-dimensional structure of the
recombinant BbCI to 1.70 A˚ resolution and compare it to
the structure of the highly homologous BbKI. The three-
dimensional structures of only a few plant Kunitz-type
inhibitors have been determined and they all display a
b-trefoil structure [18–20], composed of a six-stranded
b-barrel closed at one end by three b-hairpins and exhib-
iting a characteristic pseudo 3-fold axis of symmetry
when viewed down the b-barrel axis [21]. All representa-
tive proteins of the b-trefoil family display the same
3-fold repetition as a distinctive structural signature
although they are less than 30% identical at the amino
acid sequence level [22].
To the best of our knowledge, this is the first report of a
crystallographic structure of an inhibitor of the Kunitz
(STI) family without disulfide bridges. Given the impor-
tance of the covalent bonds in the stabilization of the reac-
tive site loop [23,24], it was important to elucidate the
rBbCI crystallographic structure in order to understand
the structural aspects surrounding its reactive site.
Results and discussion
rBbCI structure displays a beta-trefoil fold
rBbCI structure contains 164 residues, numbered from
Met (0) to Thr (163). All residues were unambiguously
resolved by electron density maps. As in contrast to classi-
cal Kunitz-type inhibitors, BbCI has no cysteine residues
and therefore no disulfide bridges, in order to further
understand the detailed structural features of this cystein-
less inhibitor we have solved the crystal structure of rBbCI
at 1.7 A˚ resolution (Fig. 1). The crystallographic structure
was refined to an R-value of 20.7% (Rfree 25.6%) using all
reflections between 26.8 and 1.7 A˚ (for a detailed view of
data collection and refinement statistics please refer to
Table 1). A detailed view of the final electron density
map is shown in Fig. 2A highlighting the overall quality
of the experimental data. The asymmetric unit contains
two molecules of rBbCI and 239 solvent molecules. The
rBbCI structure presents a typical ‘‘b-trefoil’’ fold, as
shown in Fig. 1. It is formed by six two-stranded hairpins,
three of these form a barrel structure, and the other
three are in a triangular array that caps the barrel. Thearrangement of the secondary structure gives the molecule
a pseudo 3-fold axis. The amino acid Asp16, in both mol-
ecules in the asymmetric unit, is present in generously
allowed region of the Ramachandran map [25], although
it is perfectly well defined in the electron density map. This
can be explained by the presence of a strong crystalline
contact with the region of the loop formed with the amino
Fig. 2. (A) Electron density map, contoured at 1r, of the rBbCI reactive site loop showing alanine 63 at position P1. (B) Residue Asn13 forms a network
of hydrogen bonds (dashed lines) scaffolding along with the reactive site loop (P3–P3´) of rBbCI.
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lent molecule.
Structural comparison of rBbCI with other plant Kunitz-type
inhibitors
Despite their low sequence homology, crystallographic
analyses of the Kunitz inhibitors from soybean [24], and
Erythrina caffra [23], the interleukins-1b and 1a [26] and
the acid and basic fibroblast growth factors [27] have
shown that they share this unusual fold. BbCI shares a high
structural homology with the plant Kunitz-type inhibitors
BbKI, SbTI and ETI. The inhibitors rBbCI and rBbKI
are 18 kDa proteins with high structural identity and con-
tain conserved residues characteristics of the plant Kunitz-
type inhibitor family, for example Asp5, Gly8, Pro10,
Tyr17, Tyr18, Gly28 and Gly35/Asn36/Glu37 (SbTI num-
bering), but they do not contain any disulfide bridges. The
residues Cys40, Cys80, Cys125 and Cys132 are substituted
by Glu40, Ser80, Tyr125 and Gly132 in both rBbCI and
rBbKI structures, as shown in Fig. 3. The superposition
of the structurally equivalent Ca atoms of rBbCI with
rBbKI and ETI gives an r.m.s. deviation of 0.88 and
1.9 A˚, respectively. The central scaffold is common and lar-
ger deviations occur within the surface loops where overall
sequence conservation is lower.
The major differences in rBbCI and rBbKI three-
dimensional structures is the loop which, in the case of
rBbCI, is formed by the amino acids Val78, Pro79,
Ser80, Ser81, Ser82, Asp83, Ser84, Glu85 and in rBbKI
by Gly78, Pro79, Ser80, Ser81, Ser82, Asp83, Ser84,
Gly85 (Fig. 3). The change of Val78 and Glu85 in rBbCI
to glycine in rBbKI permits different orientations in this
loop-80. rBbKI loop is more flexible while in rBbCI theloop shows less mobility and is closer to the main core
of the protein.
Structural consequences of disulfide bond replacement
In the classical Kunitz inhibitors such STI and ETI,
the two disulfide bridges are localized on the surface of
the protein, what makes them highly solvent-accessible,
but the contribution of these structures on the mainte-
nance of their functionality are on dependence of individ-
ual features of each protein. Thus, analysis of structural
differences at this position may contribute to understand
the significance of the disulfide bonds for the stability
and inhibitory specificity of the proteins. Studies which
had examined the role of disulfide bonds in the structure
and unfolding of STI showed that the reduction of the
disulfide bonds results in a fully inactive protein [28].
This result is in contrast to that shown in ETI, which
remains fully active in both the disulfide intact and
reduced states [29]. Thus, the disulfide bonds in STI play
a crucial role in protein structure stabilization necessary
to maintain enzymatic activity [28].
The absence of disulfide bridges in rBbCI and rBbKI
might result in unfolded proteins and consequent loss
of b-sheet structure. However, the replacement of
Cys39, Cys83, Cys132 and Cys139 (ETI numbering,
IDE3_ERYCA in Fig. 3) by Glu40, Ser80, Tyr125 and
Gly132 in rBbCI and rBbKI, and which allowed the for-
mation of hydrogen bonds, prevented a hydrophobic col-
lapse of the protein, as it occurs with STI after the
disulfide bonds were reduced. Tyr125 residue appears to
be important for stabilization of rBbCI and rBbKI since
the loop conformation is constrained by a water-medi-
ated hydrogen bond between the Tyr125 and Gly132
Fig. 3. The amino acid sequence alignment of rBbCI and rBbKI inhibitors with representative members of the plant-type Kunitz inhibitor family. The
alignment was performed using ClustalW [43] (http://www.ebi.ac.uk/clustalw). Conserved amino acids are boxed in white the cysteine residues are within a
black box and the amino acid in P1 is highlighted by a circle.
Fig. 4. A water-mediated hydrogen bond in Bauhinia inhibitors replace
the disulfide bridges formed between Cys132 and Cys139 in ETI (green)
rBbCI is shown in red and rBbKI in blue. The figures were prepared
with the program Pymol [44]. (For interpretation of the references in
color in this figure legend, the reader is referred to the web version of
this article.)
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bridges involving residues Cys132 and Cys139 (ETI num-
bering). In the case of rBbCI and rBbKI, our studies
clearly demonstrate that polar interaction of the protein
is involved in the maintenance of the structural folding
and therefore in the inhibitory function.
The other disulfide bridge, Cys39–Cys83 (ETI number-
ing), also common in classical plant-type Kunitz inhibitors,
apparently reduces the flexibility of the loops by cross-link-
ing the loops (loop-40 and loop-80) containing these resi-
dues. In both rBbCI and rBbKI, as a result of the
missing disulfide bond, loop-80 moves away from loop-
40, approaching the reactive site loop-60. Loop-80 is, the
most divergent loop when compared to the structure of
ETI.
Within BbKI loop-80, hydrogen bonds between Ser80
and Gly14 help to stabilize both loops, maintaining
Asn13 in position to form a hydrogen bond network
in the reactive site loop. In rBbCI, Ser80 forms a
hydrogen bond with Ser82, within the same loop. The
presence of the Gly14 in rBbKI and not in rBbCI con-
fers higher flexibility to this loop, flexibility that is com-
pensated in rBbKI by formation of a strong H-bond
with Ser80.
In rBbCI, both loops 80 and 14 contain less glycine res-
idues, therefore they are more rigid, loop-80 is internally
stabilized by contacts with Ser82 and loop-14 is stabilized
by a H-bond with the CO of Phe58 [14].
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The geometry of the carbonyl group at the P1 position is
relevant to generate an interaction between inhibitor and
protease during catalysis [30,31]. The residues adjacent to
P1 contribute to the inhibitory selectivity of the enzyme
due to the characteristics of each amino acid establishing
others interactions, such as hydrogen and saline bridges
or steric influences that are fundamental to the inhibitory
interaction. Alanine 63, identified as the P1 residue in the
putative reactive site of rBbCI was confirmed by HNE
and cruzipain/cruzain specific cleavage [11,14], as shown
in Fig. 2A and B.
The maintenance of the canonical conformation of the
reactive site loop is also considerable for the proper inhib-
itory function and protein scaffold plays a role at this posi-
tion. Owing to its crucial position, the role of a conserved
Asn (Asn13 in rBbCI and rBbKI and Asn12 in ETI) was
emphasized in the Kunitz family of inhibitors [23,24,31].
In rBbCI crystallographic structure also keeps the stability,
in addition with other interactions, of the loop formed
between Thr60, Pro61, Leu62, Ala63, Ile64 and Ala65 of
the reactive site, forming a hydrogen bond network, as
shows Fig. 4.
Studies have pointed out the positive contribution of the
hydrophobic characteristic of alanine at the P1 position for
the interaction to the subsite S1 of elastase [32,33] and of
cruzain [34]. Thus, the residue at P1 position of rBbCI reac-
tive-site (Ala63) was mutated to examine its role in the
inhibitory specificity. It was shown that this residue is
crucial for elastase and cruzain inhibitory activity since
rBbCI-A63R did not affect the enzyme substrate binding.
However, the mutant inhibitor acquired the property for
trypsin inhibition measured by the association constant,
which is in the same order of magnitude than that of rBbKI
(Kiapp 28 nM) [14], thereby supporting their reactive-site
integrity and its role in the strict selectivity of BbCI, which
is able to inhibit the serine proteases elastase and cathepsin
G but not trypsin and trypsin like proteases.
Materials and methods
Crystallization. The rBbCI was obtained as described previously [14].
Crystals were grown by vapor diffusion at 18 C temperature using the
hanging drop method, in two different crystallization buffers: 0.1 M
sodium acetate, pH 8.6 containing 0.2 M ammonium acetate and poly-
ethylene glycol 4000 (30%), (rBbCI monoclinic) and 0.1 M Hepes, pH 7.5
containing 1.5 M lithium sulphate (rBbCI triclinic). Diffraction data were
collected using a RIGAKU ultra X 18 rotating anode with a MAR345 dtb
image plate. The resulting crystal (rBbCI monoclinic) belonged to space
group p21 with cell dimensions of a = 61.96 A˚, b = 41.32 A˚, c = 63.53 A˚,
b = 98.46o and with two inhibitor molecules, related by a non-crystallo-
graphic 2-fold symmetry axis, in unit asymmetric, which was the main
object of this work (data shown in Table 1).
rBbCI triclinic crystals (space group p321) diffracted to lower resolu-
tion and data were not further used.
Data collection, processing, phasing, and refinement. rBbCI monoclinic
data were collected at IFSC Crystallography Laboratory to 1.70 A˚ reso-
lution and processed using the programs MOSFLM [35] and SCALA
[36,37] from the CCP4 package [38].The structure was solved by molecular replacement using the program
MOLREP [39] and the crystal structure of rBbKI (recombinant Bauhinia
bauhinioidesKallikrein Inhibitor) as a search model (PDB ID code 2GO2),
both structures were solved at the same time, but rBbKI structure was
determined by SIRAS [15]. Alternate rounds of model building with the
program O [40] and further refinement with the program Refmac 5.0 [41]
resulted in the final model with an Rfree an Rfactor of 25.6 and 20.7% for all
data between 26.8 and 1.70 A˚ resolutions, respectively. The model was
analyzed with Procheck [42] and showed 92.2% of the residues in core
region of the Ramachandran plot [25], while the remaining 7.4% were
present in the additionally allowed region. A single residue (Asp16) lies in
the generously allowed region in both molecules A and B, but it is per-
fectly well defined in the electron density map. Coordinates have been
deposited in the RCSB Protein Data Bank: PDB ID code 2GZB.
BbCI mutagenesis. The reactive site P1 residue encoding Ala63 was
mutated to encode Arg63 through site-directed mutagenesis using a
QuikChange Site-Directed Mutagenesis Kit (Stratagene, Germany)
(BbCI-A63R) where the pET28aBbCI DNA double-stranded and
100 pmol of each primer containing the mutation desired (BbCI-
A63R_FOWARD: 5 0-CGG TTA GAT TTG AAA CCC CAC TTC GCA
TTG CTA TAA TCA CAG AGT C-3 0 BbCI-A63R_REVERSE: 5 0-GAC
TCT GTG ATT ATA GCA ATG CGA AGT GGG GTT TCA AAT
CTA ACC G-3 0) were used. The mutant protein rBbCI-A63R was
expressed in Escherichia coli BL21 (DE3) and its specificity was assayed on
cruzain, PPE and trypsin activity as described previously for rBbCI
[8,11,12,14].
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